7.77
0.44 (6.00%)
| Previous Close | 7.33 |
| Open | 7.85 |
| Volume | 165,167 |
| Avg. Volume (3M) | 412,967 |
| Market Cap | 256,922,048 |
| Price / Book | 2.00 |
| 52 Weeks Range |
| Diluted EPS (TTM) | -12.64 |
| Total Debt/Equity (MRQ) | 6.58% |
| Current Ratio (MRQ) | 9.38 |
| Operating Cash Flow (TTM) | -62.95 M |
| Levered Free Cash Flow (TTM) | -36.83 M |
| Return on Assets (TTM) | -39.93% |
| Return on Equity (TTM) | -74.83% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Lexeo Therapeutics, Inc. | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | 5.0 |
| Insider Activity | -1.5 |
| Price Volatility | 1.5 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -0.5 |
| Average | 1.40 |
|
Lexeo Therapeutics Inc is a a clinical-stage genetic medicines company dedicated to transforming healthcare by applying pioneering science to fundamentally change how disease is treated. Its pipeline consists of candidates targeting patient populations that place significant burden on society and are most amenable to their genetic medicine approach. The Company is focused on preclinical and clinical stage gene therapies, and specifically on hereditary and acquired diseases of high unmet need which is their only business segment. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 0.49% |
| % Held by Institutions | 91.48% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 25.00 (Chardan Capital, 221.75%) | Buy |
| Median | 23.00 (196.01%) | |
| Low | 19.00 (Leerink Partners, 144.53%) | Buy |
| Average | 22.33 (187.39%) | |
| Total | 3 Buy | |
| Avg. Price @ Call | 7.69 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 14 Nov 2024 | 23.00 (196.01%) | Buy | 7.78 |
| 31 Oct 2024 | 21.00 (170.27%) | Buy | 7.90 | |
| Chardan Capital | 13 Nov 2024 | 25.00 (221.75%) | Buy | 7.64 |
| 30 Oct 2024 | 23.00 (196.01%) | Buy | 8.28 | |
| Leerink Partners | 13 Nov 2024 | 19.00 (144.53%) | Buy | 7.64 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| TOWNSEND RICHARD NOLAN | - | 8.36 | -2,500 | -20,900 |
| Aggregate Net Quantity | -2,500 | |||
| Aggregate Net Value ($) | -20,900 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 8.36 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| TOWNSEND RICHARD NOLAN | Officer | 10 Dec 2024 | Automatic sell (-) | 2,500 | 8.36 | 20,900 |
| TOWNSEND RICHARD NOLAN | Officer | 10 Dec 2024 | Option execute | 2,500 | - | - |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2024 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |